MODERN CLINICAL PHARMACOLOGY APPROACHES TO NEGATIVE SYMPTOM TREATMENT IN SCHIZOPHRENIA
DOI:
https://doi.org/10.31082/1728-452X-2020-217-218-7-8-53-61Keywords:
schizophrenia, negative disorders, antipsychotics, cariprazineAbstract
Negative symptoms contribute to poor functional outcomes and quality of life for individuals with schizophrenia.
Efficacy of negative symptom treatment in patients with schizophrenia are discussed by the example of a new atypical antipsychotic cariprazine (Reagila®).
Discussion. Improved Receptor Profile: high affinity for D3 receptors and partial agonism for both dopamine receptor subtypes, may act as a basic mechanism for improving negative symptoms and cognitive impairment.
Сonclusions. Сariprazine is the drug of choice in the treatment of adult patients both at the onset of the disease with a predominance of negative disorders, and in the chronic course of schizophrenia with positive and negative symptoms, especially in patients with a high risk of metabolic and cardiovascular disorders.
References
Statisticheskii sbornik Respublikanskii nauchno-prakticheskii tsentr psikhicheskogo zdorovia «Psikhiatricheskaia pomoshch naseleniiu RK»; 2017-2018. [Statistical collection of the Republican Scientific and Practical Center for Mental Health "Psychiatric assistance to the population of the Republic of Kazakhstan"; 2017-2018]. Available from: http://mentalcenter.kz/images/Statsbornik/Stat_sbornik_2017_2018_psych.docx
Altynbekov KS, Neznanov NG. Sovremennye podkhody k optimizatsii psikhiatricheskoi pomoshchi bolnym shizofreniei v Respublike Kazakhstan. [Modern approaches to the optimization of psychiatric care for patients with schizophrenia in the Republic of Kazakhstan]. Almaty: Publishing house LLP "Artikul"; 2017. 184 p.
Szkultecka-Dębek M, Walczak J, Augustyńska J. Epidemiology and Treatment Guidelines of Negative Symptoms in Schizophrenia in Central and Eastern Europe: A Literature Review. Clin Pract Epidemiol Ment Health. 2015;23(11):158–165. DOI: 10.2174/1745017901511010158
Becker RA, Bykov YuV, Morozov PV. Vydaiushchiesia psikhiatry XX veka [Outstanding psychiatrists of the XX century]. M.: Publishing House Gorodets; 2019. 256 p.
Becker RA, Bykov YuV, Morozov PV. Cariprazine as a socializing drug in schizophrenia (A Literature Review). Psikhiatriia i psikhofarmakoterapiia im. P.B. Gannushkina =Psychiatry and psychopharmacotherapy. 2020;22(2):16-24. (In Russ.)
Frye RE. Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents. CNS Drugs. 2018;32(8):713-734. DOI: 10.1007/s40263-018-0556-y
Harvey PD, Kleefe RS, Eesley CE. Neurocognition in Schizophrenia. In: Sadock BJ, Sadok VA, Raiz P. Kaplan & Sadock,s Comprehensive Textbook of Psychiatry, 2017.
Kirschner M. Secondary negative symptoms - A review of mechanisms, assessment and treatment. Schizophr Res. 2017;186:29-38. DOI: 10.1016/j.schres.2016.05.003
Bykov YuV, Becker RA, Morozov PV. The efficacy of cariprazine in the treatment of schizophrenia, especially with prominent or predominant negative symptoms. Psikhiatriia i psikhofarmakoterapiia im. P.B. Gannushkina = Psychiatry and psychopharmacotherapy. 2018;20(5):27-37. (In Russ.)
Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Lippincott Williams & Wilkins (LWW), 2017. ISBN: 978-1-45-110047-1
Pyatnitskiy NYu. «Primary», «basic» and «secondary» symptoms of schizophrenia in the concept of E. Bleuler. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = SS Korsakov Journal of Neurology and Psychiatry. 2017;117(8):88-97. (In Russ.). DOI: 10.17116/jnevro20171178188-97
Мосолов С.Н., Ялтонская П.А. Алгоритм терапии первичной негативной симптоматики при шизофрении // Современная терапия психических расстройств. - 2020. - №2. – C. 2-10. DOI: 10.21265/PSYPH.2020.26.17.001
Ktwis SF, Escalona R, Kcith SJ. Phenomenology of Schizophrenia. In: Sadock BJ, Sadok VA, Raiz P. Kaplan & Sadock,s Comprehensive Textbook of Psychiatry; 2017.
Mier D, Kirsch P. Social-Cognitive Deficits in Schizophrenia. Curr Top Behav Neurosc. 2017;30:397-409. DOI: 10.1007/7854_2015_427
Marder SR, Garderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017;16(1):14-24. DOI: 10.1002/wps.20385
Durgam S, Earley W, Lu K, et al. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. Int J Clin Pract. 2017;71(12): e13037. DOI: 10.1111/ijcp.13037
Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017;7(1): 29–41. DOI: 10.1177/2045125316672136
Roberts RJ, Findlay LJ, El-Mallakh PL, El-Mallakh RS. Update on schizophrenia and bipolar disorder: focus on cariprazine. Neuropsychiatr Dis Treat. 2016;12:1837–42. DOI: 10.2147/NDT.S97616
De Deurwaerdère P. Cariprazine: New dopamine biased agonist for neuropsychiatric disorders. Drugs Today (Barc). 2016;52(2):97–110. DOI: 10.1358/dot.2016.52.2.2461868
Citrome L. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist. Clin Schizophr Relat Psychoses. 2016;10(2):109–19. DOI: 10.3371/1935-1232-10.2.109
Scarff JR. The prospects of cariprazine in the treatment of schizophrenia. Ther Adv Psychopharmacol. 2017;7(11):237–239. DOI: 10.1177/2045125317727260
EMA. EMA Public Assessment Report on Reagila; 2017. Available from: https://www.ema.europa.eu/documents/assessment-report/reagila-eparpublic-assessment-report_en.pdf.
Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placeboand active-controlled trial. J Clin Psychiatry. 2015;76(12): e1574–e1582. DOI: 10.4088/JCP.15m09997
Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an International, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–373. DOI: 10.1097/JCP.0000000000000346.
Citrome L, Durgam S, Lu K, et al. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trial. J Clin Psychiatry. 2016;77(1):109–115. DOI: 10.4088/JCP.15m10192
Earley W, Durgam S, Lu K, et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017;32(6):319–328. DOI: 10.1097/YIC.0000000000000187
Zhao MJ, Qin B, Wang JB, et al. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol. 2018;38(1):55–59. DOI: 10.1097/JCP.0000000000000834
Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2–3):264–271. DOI: 10.1016/j.schres.2016.06.030
Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–13. DOI: 10.1016/S0140-6736(17)30060-0
Durgam S, Greenberg WM, Li D, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl). 2017;234(2):199–209. DOI: 10.1007/s00213-016-4450-3
Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7):625-639. DOI: 10.1007/s00406-018-0869-3
